Abstract
Introduction: Glecaprevir/pibrentasvir is a fixed-dose combination regimen of a new generation NS3/4A inhibitor and an NS5A inhibitor with potent anti......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
